A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Phase 3 Completed 1024 enrolled Restorbio Inc.

RandomizedParallel-groupTriple-blindPrevention

Summary

To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.

Timeline

Start: 2019-04-15
Primary completion: 2019-12-02
Completion: 2019-12-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dactolisib	Small molecule	10 mg	—

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Summary

Timeline

Drugs

Indications